(Q35987384)

11 August 2017

Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans (English)

1 reference

11 August 2017

Ng-Mak DS

1

1 reference

11 August 2017

Hu XH

2

1 reference

11 August 2017

Chen Y

3

1 reference

11 August 2017

Ma L

4

1 reference

11 August 2017

Solomon G

5

1 reference

11 August 2017

language of work or name

1 reference

30 May 2007

1 reference

International Journal of Clinical Practice

11 August 2017

1 reference

11 August 2017

61

1 reference

11 August 2017

7

1 reference

11 August 2017

1091-1111

1 reference

Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Acute drug treatment of migraine attack

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Real-world experiences in migraine therapy with rizatriptan

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Migraine: diagnosis and management.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1974799

Comparison of rizatriptan and other triptans on stringent measures of efficacy

2 October 2017

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2007.01400.X

A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17537184

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Guidelines for controlled trials of drugs in migraine: second edition

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17537184

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1742-1241.2007.01400.X

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

17537184

1 reference